Treatment of Corneal Epithelium Lesions with Plasma Rich in Growth Factors: A Case Series and Implications

<b>Purpose:</b> The human eye is a remarkable organ that develops from many tissues originating from neuroectodermal, ectodermal, and mesodermal sources. If any of these essential ocular tissues are impaired, it can lead to complete vision loss. Thus, the objective of these case studies is to evaluate the impact of growth factor-rich plasma (PRGF) on the healing process of corneal epithelial injuries. <b>Methods:</b> This case series includes three patients with corneal epithelium lesions. The patients were treated with hyaluronic acid and matrix-regenerating agent eye drops for seven days. For a minimum of six more weeks, additional cycles of PRGF eye drops were administered. <b>Results:</b> All three patients demonstrated improvements in visual acuity, reductions in ocular symptoms, and enhanced ocular surface health. In Patient 1, a good postoperative response was obtained after a second surgery. In Patient 2, after 30 days, the corneal leucoma showed a good response and complete recovery. In Patient 3, the ulcer and visual acuity improved 72 h after the treatment began. <b>Conclusions:</b> PRGF eye drops demonstrated efficacy and safety in the treatment of noninfectious corneal ulcers. Additionally, when used in conjunction with other therapies, they have the potential to augment the healing process of corneal ulcers.